Coronavirus disease 2019 (Covid-19) is the worst pandemic in the past 100 years spanning more than 200 countries \[[@CIT0001]\] and affecting millions of individuals worldwide \[[@CIT0002]\]. The novel severe acute respiratory syndrome coronavirus (SARS-CoV-2) was identified as the causative agent of Covid-19, with angiotensin-converting enzyme 2 (ACE2) as one of its cellular receptors \[[@CIT0003]\]. Covid-19 has a spectrum of clinical manifestations ranging from asymptomatic or mildly symptomatic in about 80% of those affected according to community surveys to an approximate 2% case fatality rate in the hospitalized populations \[[@CIT0004]\]. Although the statistical estimations are changing daily, more than 11 million people have been affected by Covid-19, resulting in more than half a million deaths across the world by July 7, 2020 \[[@CIT0001], [@CIT0006]\].

A great risk of severe Covid-19 has been reported in patients with diabetes and hypertension \[[@CIT0008]\]. One study of 191 patients reported a mortality risk of 2.85-fold and 3.05-fold for those with diabetes and hypertension, respectively \[[@CIT0009]\]. Furthermore, the Chinese Center for Disease Control reported a higher case fatality rate for persons with diabetes compared with those without (7.3%. vs 2.3%, respectively) \[[@CIT0007]\]. This risk may be explained by a dysregulated immune response, a higher comorbidity burden, and alterations of ACE2 cellular expression \[[@CIT0006], [@CIT0010]\]. The latter has been the subject of intense scrutiny, given the lack of evidence against the use of renin-angiotensin system blocking agents and their known benefits in diabetes and hypertension \[[@CIT0012]\], as well as other cardiovascular conditions that have been shown to enhance ACE2 expression \[[@CIT0015]\].

Previous systematic reviews reported a prevalence of diabetes and hypertension in patients with Covid-19 ranging from 9.7% to 11.9% and 17.1% to 20%, respectively \[[@CIT0016]\]. The risks of severe Covid-19 in patients with diabetes and hypertension were \~3 and \~2-fold, respectively \[[@CIT0016], [@CIT0020]\]. However, these reports failed to address the high probability of including repeated information and patient duplicates in the analysis and thus may lead to inaccurate effect sizes and misleading results \[[@CIT0016], [@CIT0018]\]. This has been listed by authors as a major limitation \[[@CIT0020]\], and has raised major editorial concerns \[[@CIT0022]\]. Ultimately, risk estimates remain uncertain. Therefore, we systematically assessed the prevalence of diabetes and hypertension in patients with Covid-19 after excluding repeated patients across studies and analyzed the associated risks for Covid-19 severity, intensive care unit (ICU) admission and mortality.

Methods {#s1}
=======

Protocol registration {#s2}
---------------------

This systematic review adheres to the standards set in the Meta-analysis of Observational Studies in Epidemiology and Preferred Reported Items for Systematic Reviews and Meta-Analysis \[[@CIT0025], [@CIT0026]\]. Registration ID is CRD42020176582 and is available at: <https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=176582>.

Eligibility criteria {#s3}
--------------------

For our first aim, we included observational and interventional studies that reported the frequency of diabetes and/or hypertension in adult population with Covid-19. For our second aim, we included studies that reported exposure-outcome association as univariate or multivariate analysis, with diabetes, hypertension being the exposure, and severe Covid-19 through ICU admissions or mortality being the outcome of interest. We excluded case reports (n \< 2) and studies including pregnant women and pediatric populations (age \< 18 years). We did not set a criterion based on Covid-19 diagnosis definition, exposure ascertainment, or outcome definition because these were expected to be different and/or with limited rigor.

Search strategy {#s4}
---------------

An experienced librarian (N.A.V.), with input from investigators, searched several databases for peer-reviewed manuscripts in English published between December 1, 2019, and April 6, 2020, including Ovid Medline In-Process & Other Non-Indexed Citations, Ovid Medline, Ovid Embase, Ovid Cochrane Central Register of Controlled Trials, Ovid Cochrane Database of Systematic Reviews, and Scopus. Manual screening of references from the included studies was performed \[[@CIT0027]\]. All supplementary material and figures are located in adigital research materials repository \[[@CIT0027]\].

Selection process and data extraction {#s5}
-------------------------------------

Search results were uploaded into an online software program (DistillerSR; Evidence Partners, Ottawa, ON, Canada). Reviewers, working independently and in duplicate, screened studies for eligibility using standardized and prepiloted instructions in a round of title and abstract and one of full-text screening. In round 1, disagreements were included; and in round 2, disagreements were resolved by consensus or arbitration by a third investigator (F.H.S.). To identify articles with high probability of patient repetition, studies that were included after full-text screening followed a preliminary data extraction conducted by 2 pairs of investigators. We extracted the timeframes of each study, hospital(s), location(s), country of origin, and the list of authors. Next, the enrollment timeframes from the studies were plotted with the information of the hospital(s). Studies without overlap in the plot were included for all outcomes. If studies overlapped, we analyzed outcomes reported by each study. If outcomes were repeated in overlapping studies, we included the data for outcomes (or frequency of comorbidities) from the study with the largest sample \[[@CIT0027]\]. Data extraction was also performed in an independent and duplicated manner using a standardized and prepiloted.

Risk of bias and confidence in the body of evidence {#s6}
---------------------------------------------------

For case series, we modified 2 tools and analyzed: selection, ascertainment of outcomes and exposures, causality, and reporting \[[@CIT0028], [@CIT0029]\]. For case control studies, the Newcastle-Ottawa Scale was used \[[@CIT0030]\]. The quality of evidence for each outcome was determined using the Grading of Recommendations Assessment, Development and Evaluation approach \[[@CIT0031]\]. Both risk of bias and overall quality of evidence assessment were performed independently and in duplicate. Disagreements were resolved by consensus between the 2 reviewers, or by arbitration by a third author (R.R.G.) \[[@CIT0027]\]. Full details are listed elsewhere \[[@CIT0027]\].

Data synthesis {#s7}
--------------

We estimated the full-text screening inter-rater reliability with the Cohen's kappa statistic. To estimate the prevalence, we used a binomial-normal model for meta-analysis of proportions (i.e., generalized linear mixed model) \[[@CIT0032], [@CIT0033]\]. We calculated the relative risk (RR) for each outcome and performed a meta-analysis results using a random-effect models and the restricted maximum-likelihood estimator \[[@CIT0034]\]. Meta-analysis of unadjusted and adjusted estimates was not combined. We were unable to calculate adjusted estimates because of scarcity of data. Inconsistency for each outcome, not attributable to chance, was assessed visually using forest plots and estimated using the percentage of variance in a meta-analysis that is attributable to study heterogeneity (*I*^2^) statistic: *I*^2^ \< 25% and \> 75% reflects low and high inconsistency, respectively \[[@CIT0035]\]. All statistical analyses were performed in R (R Foundation for Statistical Computing, Vienna, Austria) \[[@CIT0036]\].

Analysis of subgroups and sensitivity {#s8}
-------------------------------------

Details on all predefined and nonpredefined subgroup and sensitivity analyses are listed separately \[[@CIT0027]\]. To identify confounders, we designed a directed acyclic graph (DAG) in R \[[@CIT0027], [@CIT0037]\].

Results {#s9}
=======

Search strategy yielded 5484 studies. After deduplication and screening, 122 studies fulfilled our selection criteria (**[Fig. 1](#F1){ref-type="fig"}**). Full-text screening inter-observer agreements were substantial (k = 0.77, 0.80, and 0.84 for each pair of reviewers). We identified 93 articles at high probability of repeating patients. From those, we fully excluded 57 (47%), and partially (some outcomes included) excluded some outcomes in 36 (30%) \[[@CIT0027]\]. Ultimately, 65 (15 794 patients) were included in our analysis. Overall, 18 (28%) studies had low risk of bias, 3 (4%) had some concerns, and 44 (68%) had high risk. For prevalence, 40 (62%) studies resulted at low risk of bias, 1 (1%) at some concerns, and 24 (37%) at high risk. Overall confidence in the body of evidence is graded as low \[[@CIT0027]\]. We did not assess risk of publication bias through the funnel plot because of the limited number of studies \[[@CIT0022]\].

![Flow chart of the selection process.](bvaa102f0001){#F1}

Characteristics of included studies {#s10}
-----------------------------------

Most studies were retrospective case series (97%) performed at a single center (63%) in China (71%), with inpatients (43%) diagnosed with Covid-19 using RT-PCR (**[Table 1](#T1){ref-type="table"}**) (97%). Most articles described treatments, which included standard of care (38%) and supplemental antiviral therapy (42%). Study length was reported in most studies (75%; 9-65 days). Percentage of males varied between 0 and 88, and the mean age ranged from 33 to 75 years. A total of 5 studies (8%) reported ethnicity.

###### 

Characteristics of the Included Studies

  No.   ID      Author             Publishing Date   Country             Study Design                Selection Criteria   Setting                                Centers       Sample Size   Males, n (%)   Age, Mean ± SD   Molecular Diagnosis
  ----- ------- ------------------ ----------------- ------------------- --------------------------- -------------------- -------------------------------------- ------------- ------------- -------------- ---------------- ---------------------
  1     43      Grasselli et al.   4/6/20            Italy               Retrospective case series   Severe (ICU)         Inpatient                              Multicenter   1043          1304 (82)      63 ± 10          RT-PCR
  2     44      Wang et al.        4/3/20            China               Retrospective case series   General              Outpatient                             Single        1012          524 (52)       50 ± 14          RT-PCR
  3     489     COVID-19 NIRST     3/4/20            Australia           Retrospective case series   General              Community                              Multicenter   23            13 (52)        48 ± 18          NA
  4     1405    Fried et al.       4/3/20            USA                 Retrospective case series   General              Inpatient                              NR            4             2 (50)         54 ± 12          NA
  5     7916    Zhang et al.       2/17/20           China               Retrospective case series   General              Inpatient                              Single        140           71 (51)        57 ± 10          RT-PCR
  6     7929    Liu et al.         2/9/20            China               Retrospective case series   General              Inpatient                              Single        12            8 (67)         53 ± 18          RT-PCR
  7     7942    Chan et al.        1/24/20           China               Retrospective case series   General              Inpatient                              Single        6             3 (50)         46 ± 22          RT-PCR
  8     7949    Xu et al.          2/28/20           China               Retrospective case series   General              Inpatient                              Single        90            39 (43)        50 ± 11          RT-PCR
  9     8070    Pung et al.        3/28/20           Singapore           Retrospective case series   General              Outpatient                             Multicenter   17            7 (41)         40 ± 11          NA
  10    8149    KSID et al.        3/24/20           Republic of Korea   Retrospective case series   Death patients       Community                              Multicenter   54            33 (61)        75 ± 10          NA
  11    8236    Long et al.        3/15/20           China               Retrospective case series   General              Inpatient                              Single        10            3 (30)         54 ± 27          RT-PCR
  12    8264    Qui et al.         4/2/20            China               Retrospective case series   Severe (ICU)         Inpatient                              Single        10            0 (0)          65 ± 9           RT-PCR
  13    8405    Wang et al.        3/31/20           China               Retrospective case series   General              Inpatient                              Single        116           67 (58)        54 ± 22          RT-PCR
  14    8424    Zhang et al.       3/31/20           China               Retrospective case series   Severe (critical)    Inpatient                              Multicenter   4             2 (50)         57 ± 18          RT-PCR
  15    8525    Meng et al.        3/31/20           China               Retrospective case series   General              Inpatient                              Single        42            24 (57)        64 ± 10          RT-PCR
  16    8542    Escalera et al.    4/2/20            Bolivia             Retrospective case series   General              Both in- and out-patient               Multicenter   12            6 (50)         36 ± 15          RT-PCR
  17    8581    Kim et al.         4/6/20            Republic of Korea   Retrospective case series   General              Inpatient                              Multicenter   28            15 (54)        43 ± 13          RT-PCR
  18    8586    Lescure et al.     3/27/20           France              Retrospective case series   General              Inpatient                              Multicenter   5             3 (60)         47 ± 20          RT-PCR
  19    8606    Wang et al.        3/30/20           China               Retrospective case series   General              Inpatient                              Single        339           166 (49)       69 ± 8           RT-PCR
  20    8609    Mo et al.          3/16/20           China               Retrospective case series   General              Inpatient                              Single        155           86 (55)        54 ± 18          NA
  21    8645    Wang et al.        3/31/20           China               Retrospective case series   General              Inpatient                              Single        5             3 (60)         61 ± 8           RT-PCR
  22    8680    Young et al.       3/3/20            Singapore           Retrospective case series   General              Inpatient                              Multicenter   18            9 (50)         47 ± 10          RT-PCR
  23    8691    Shen et al.        3/27/20           China               Prospective case series     Severe (ARDS)        Inpatient                              Single        5             3 (60)         54 ± 15          RT-PCR
  24    8816    To et al.          3/23/20           Hong Kong           Retrospective case series   General              Inpatient                              Multicenter   23            13 (57)        62 ± 19          RT-PCR
  25    8844    Yuan et al.        3/19/20           China               Retrospective case series   General              Inpatient                              Single        27            12 (44)        60 ± 16          RT-PCR
  26    8898    Fang et al.        3/21/20           China               Retrospective case series   General              Inpatient                              Single        32            16 (50)        41 ± 15          RT-PCR
  27    8920    Liu et al.         3/12/20           China               Retrospective case series   General              Inpatient                              Single        10            4 (40)         43 ± 10          RT-PCR
  28    8965    Zhao et al.        3/12/20           China               Retrospective case series   General              Inpatient                              Multicenter   19            11 (58)        48 ± 21          RT-PCR
  29    8969    Lu et al.          3/17/20           China               Retrospective case series   General              Inpatient                              Single        5             1 (20)         52 ± 9           RT-PCR
  30    9041    Wang et al.        2/7/20            China               Retrospective case series   General              Inpatient                              Single        138           75 (54)        56 ± 19          RT-PCR
  31    9056    Chen et al.        3/30/20           China               Retrospective case series   General              Inpatient                              Single        22            14 (64)        37 ± 18          RT-PCR
  32    9094    Ye et al.          4/2/20            China               Retrospective case series   General              Inpatient                              Single        5             3 (60)         40 ± 14          RT-PCR
  33    9113    Wang et al.        3/23/20           China               Retrospective case series   General              Inpatient                              Single        114           58 (51)        53 ± 9           RT-PCR
  34    9122    Guo et al.         3/31/20           China               Retrospective case series   General              Inpatient                              Single        174           20 (11)        61 ± 9           RT-PCR
  35    9123    Zhang et al.       3/20/20           China               Retrospective case series   General              Inpatient                              Multicenter   645           328 (51)       41 ± 15          RT-PCR
  36    9125    Wang et al.        3/5/20            China               Retrospective case series   General              Inpatient                              Single        18            10 (56)        39 ± 19          RT-PCR
  37    9151    Zhu et al.         3/13/20           China               Retrospective case series   General              Inpatient                              Multicenter   32            NA             46 ± 13          RT-PCR
  38    9171    Cai et al.         4/2/20            China               Retrospective case series   General              Inpatient                              Single        298           145 (48)       48 ± 21          RT-PCR
  39    9174    Sun et al.         3/25/20           Singapore           Case control                General              Inpatient                              Single        54            29 (54)        42 ± 15          RT-PCR
  40    9175    Cao et al.         4/2/20            China               Retrospective case series   General              Inpatient                              Single        102           53 (52)        54 ± 22          RT-PCR
  41    9198    Ren et al.         2/11/20           China               Retrospective case series   Severe (ARDS)        Inpatient                              Single        5             3 (60)         54 ± 10          RT-PCR
  42    9307    Guo et al.         3/27/20           China               Retrospective case series   General              Inpatient                              Single        187           91 (49)        59 ± 15          RT-PCR
  43    9314    Arentz et al.      3/19/20           USA                 Retrospective case series   Severe (ICU)         Inpatient                              Single        21            11 (52)        70 ± 12          RT-PCR
  44    9321    Zhang et al.       3/26/20           China               Retrospective case series   General              Inpatient                              Multicenter   28            17 (61)        65 ± 10          RT-PCR
  45    9332    NCCE et al.        3/13/20           Iran                Retrospective case series   Death patients       Community                              Multicenter   514           6629 (58)      54 ± 16          RT-PCR
  46    9339    Ding et al.        3/20/20           China               Retrospective case series   General              Inpatient                              Single        5             2 (40)         50 ± 10          NA
  47    9340    Albarello et al.   2/26/20           Italy               Retrospective case series   General              Inpatient                              Single        2             1 (50)         66 ± 1           RT-PCR
  48    9377    Zhang et al.       3/26/20           China               Retrospective case series   General              Inpatient                              Single        17            8 (47)         49 ± 13          RT-PCR
  49    9400    Wei et al.         2/28/20           China               Retrospective case series   General              Inpatient                              Multicenter   78            39 (50)        33 ± 18          RT-PCR
  50    9431    Shi et al.         3/25/20           China               Retrospective case series   General              Inpatient                              Single        416           205 (49)       64 ± 12          RT-PCR
  51    9446    Wang et al.        3/30/20           China               Retrospective case series   Severe (ARDS)        Inpatient                              Multicenter   17            7 (41)         65 ± 14          RT-PCR
  52    9496    Xin et al.         3/30/20           China               Retrospective case series   General              Inpatient                              Single        8             6 (75)         64 ± 18          NA
  53    9608    CDC COVID-19 RT    4/3/20            USA                 Retrospective case series   General              Inpatient, outpatient, and community   Multicenter   7162          NA             NA               RT-PCR
  54    9609    Iwasawa et al.     3/31/20           Japan               Retrospective case series   General              Inpatient                              Single        6             2 (33)         69 ± 3           RT-PCR
  55    9622    Liu et al.         3/27/20           China               Retrospective case series   General              Inpatient                              Single        56            31 (55)        58 ± 13          RT-PCR
  56    9667    Guan et al.        3/26/20           China               Retrospective case series   General              Inpatient                              Multicenter   1590          904 (57)       49 ± 16          RT-PCR
  57    9679    Wong et al.        3/27/20           Hong Kong           Retrospective case series   General              Inpatient                              Multicenter   64            26 (41)        56 ± 19          RT-PCR
  58    9695    Hu et al.          3/4/20            China               Retrospective case series   General              Inpatient                              Single        24            8 (33)         33 ± 28          RT-PCR
  59    9702    Xie et al.         4/2/20            China               Retrospective case series   General              Inpatient                              Single        79            44 (56)        60 ± 13          NA
  60    9764    Xu et al.          3/13/20           China               Retrospective case series   General              Inpatient                              Single        51            25 (49)        42 ± 20          RT-PCR
  61    10641   Liu et al.         3/23/20           China               Retrospective case series   Severe (ICU)         Inpatient                              Single        8             7 (88)         63 ± 11          RT-PCR
  62    10782   Gao et al.         3/17/20           China               Retrospective case series   General              Inpatient                              Single        43            26 (60)        44 ± 12          RT-PCR
  63    10860   McMichael et al.   3/27/20           USA                 Retrospective case series   General              Both in- and outpatient                Multicenter   167           55 (33)        72 ± 13          RT-PCR
  64    10861   Bai et al.         3/10/20           China               Case control                General              Inpatient                              Multicenter   219           119 (54)       45 ± 15          RT-PCR
  65    1       CDC COVID-19 RT    4/8/20            USA                 Retrospective case series   General              Inpatient                              Multicenter   159           NA             NA               NA

General selection criteria were patients hospitalized because of pneumonia caused by SARS-CoV-2.

ARDS, acute respiratory distress syndrome; ICU, intensive care unit; NA, not available; NR, not reported.

Only 69% of studies reported their definition of severity. Among those that did report severity definitions, 78% of their definitions were derived from established guidelines \[[@CIT0027]\]. Moreover, only 6 of the studies (9%) described the subtype of diabetes (type 2 diabetes), and 1 study (2%) defined the subtype of hypertension (primary hypertension). Finally, none of the included studies provided a definition for diabetes or hypertension.

Prevalence and risks of diabetes and hypertension {#s11}
-------------------------------------------------

### Quantitative synthesis.  {#s12}

The overall prevalence was 12% (95% confidence interval \[CI\], 10-15; n = 12 870; *I*^2^: 89%) for diabetes, 17% (95% CI, 13-22; n = 12 709; *I*^2^: 95%) for hypertension, and 12% (95% CI, 6-22; n = 54; *I*^2^: 0%) for coexisting diabetes and hypertension (**[Fig. 2](#F2){ref-type="fig"}**). The RR of patients with diabetes to develop our outcomes of interest were: Covid-19 severity (1.50; 95% CI, 0.90-2.50; n = 1991; *I*^2^: 74%; *P* = .118), ICU admission (1.96; 95% CI, 1.19-3.22; n = 8890; *I*^2^: 80%; *P* = .007), and mortality (2.78; 95% CI, 1.39-5.58; n = 2058; *I*^2^: 75%; *P* = .004). For patients with hypertension: Covid-19 severity (1.48; 95% CI, 0.99-2.23; n = 2023; *I*^2^: 69%; *P* = .058), ICU admission (2.95; 95% CI, 2.18-3.99; n = 1737; *I*^2^: 0%; *P* \< .001), and mortality (2.39; 95% CI, 1.54-3.73; n = 3107; *I*^2^: 66%; *P* \< .001). Furthermore, for patients with diabetes and hypertension, RR for Covid-19 severity was 10 (95% CI, 0.94-105.92; n = 22; *I*^2^: not applicable; *P* = .056).

![**Prevalence of diabetes and hypertension, overall and by subgroups.** Five studies in the diabetes, and 3 in the hypertension overall prevalence were not included in subgroups as they did not specify their setting. Nonsurvivor patients in diabetes were not included in the overall prevalence. Severe Covid-19 patients are also included in the inpatient subgroup prevalence; these patients were those from studies that included only severe, critical, or ICU patients, with or without acute respiratory distress syndrome. All patients included in the overall prevalence for the diabetes and hypertension population were inpatients. Covid-19, coronavirus disease 2019; ICU, intensive care unit.](bvaa102f0002){#F2}

### Narrative synthesis.  {#s13}

Adjusted and unadjusted estimates for mortality (hazard ratio) in patients with diabetes were nonconclusive in 2 studies (0.75; 95% CI, 0.38-1.50; n = 416; *P* = .420) \[[@CIT0042]\] and (1.09; 95% CI, 0.57-2.08; n = 339; *P* = .799) \[[@CIT0043]\]. Moreover, an adjusted odds ratio for severe Covid-19 in patients with hypertension reported by a study was 2.71 (95% CI, 1.32-5.59; n = 487; *P* = .007) \[[@CIT0043]\]. Finally, another study reported an unadjusted hazard ratio that was inconclusive in determining the risk of severe Covid-19 associated with diabetes and hypertension (1.49; 95% CI, 0.92-2.44; n = 339; *P* = .109) \[[@CIT0043]\]. Adjusted estimates are displayed along with our results for visual comparison in **[Fig. 3](#F3){ref-type="fig"}**.

![**Risk estimates for severe Covid-19, intensive care unit admission, and mortality.** RR = relative risk. HR = hazard ratio. \*Adjusted for age, preexisting cardiovascular disease (hypertension, coronary heart disease, and chronic heart failure), cerebrovascular disease, chronic obstructive pulmonary disease, renal failure, cancer, acute respiratory distress syndrome, creatine levels, NT-proB-type natriuretic peptide levels, and cardiac injury. \*\*Adjusted for time to admission.](bvaa102f0003){#F3}

Sensitivity analyses {#s14}
--------------------

### Predefined sensitivity analyses.  {#s15}

After excluding studies at high risk of bias, the overall prevalence of diabetes (12.4%; 95% CI, 9.5-16; n = 12 077/12 870; *I*^2^: 93%; 22/31 studies) and hypertension (16.8%;95% CI, 11.5-23.7; n = 11 912/12 709; *I*^2^: 96%; 25/37 studies) was similar. Moreover, in patients with hypertension, RR for severe Covid-19 remained the same but heterogeneity decreased (1.40; 95% CI, 0.65-3.00; n = 53/2023; *I*^2^: 0%; *P* = .389, 2/8 studies), whereas the risk for ICU admission decreased (2.62; 95% CI, 1.45-4.75; n = 143/1733; *I*^2^:15%; *P* = .001; 2/3 studies), and mortality increased (3.24; 95% CI, 1.27-8.28; n = 32/2063; *I*^2^: 9%; *P* = .014; 2/5 studies).

After excluding single-center studies from the analysis, RR for severe Covid-19 among patients with diabetes increased (2.1; 95% CI, 1.20-3.66; n = 1613/1991; *I*^2:^ 33%; *P* = .009; 2/6 studies). In contrast, RR for ICU admission decreased (1.80; 95% CI, 0.90-3.61; n = 8752/8890; *I*^2^: 88%; *P* = .096; 2/3 studies). Additionally, in patients with hypertension, RR for severe Covid-19 increased (2.55; 95% CI, 2.06-3.16; n = 1613/2023; *I*^2^: 0%; *P* \< .0001; 2/8 studies); for ICU admission decreased (2.70; 95% CI, 1.58-4.60; n = 1595/1733; *I*^2^: 20%; *P* = .0002; 2/3 studies); and, for mortality increased (3.32; 95% CI, 1.36-8.10; n = 1595/2063; *I*^2^: 13%; *P* = .008; 2/5 studies).

Non-predefined sensitivity analyses {#s16}
-----------------------------------

Because there was high variability in the definition of severe Covid-19 used by authors, we analyzed the risk for severe Covid-19 after including only those studies that defined severity according to the World Health Organization definition \[[@CIT0044]\] or that of the novel coronavirus pneumonia prevention and control program (6th ed.) \[[@CIT0027], [@CIT0045]\]. The RR resulted in similar estimates but decreased heterogeneity in diabetes (0.97; 95% CI, 0.65-1.46; n = 335; *I*^2^: 0%; *P* = .886), and hypertension (1.03; 95% CI, 0.67-1.57; n = 345; *I*^2^: 38%; *P* = .909). The complete description of sensitivity analysis is provided separately \[[@CIT0027]\].

Minimal sufficient adjustment sets {#s17}
----------------------------------

According to our DAG, conditioning age and obesity is necessary to analyze the effect of diabetes on mortality, whereas for hypertension, age, diabetes, and obesity are necessary \[[@CIT0027]\].

Discussion {#s18}
==========

Main findings {#s19}
-------------

Our results suggest an overall prevalence of 12% and 17% for diabetes and hypertension (respectively) among nonpregnant, adult patients with Covid-19, respectively. Additionally, these comorbidities were associated with an increased risk for ICU admission and mortality. We found an overwhelming proportion of studies at high risk of data repetition, which indicates a high risk of misrepresentation of estimates in previous systematic reviews that did not address this issue \[[@CIT0016], [@CIT0018]\]. The body of evidence comprises observational studies at moderate to high risk of bias yielding low confidence in the estimates.

Strengths and limitations {#s20}
-------------------------

We developed a methodology to identify publications at high risk of patient repetition, which, compared with previous systematic reviews, provides a major strength to the current analysis \[[@CIT0016], [@CIT0018]\]. Moreover, we also analyzed and grouped the various definitions used for severe Covid-19. From this, we conclude that this outcome lacks interpretability and therefore clinical significance because of the large heterogeneity in the definitions used. Hence, previous systematic reviews that have analyzed this outcome individually or as part of a composite, suffer from this limitation \[[@CIT0016], [@CIT0018]\]. Furthermore, although we could not perform a thorough isolation of the effect of comorbidities, we identified major confounders of our estimates using DAG \[[@CIT0046]\].

Our study has several limitations. The effects of diabetes and hypertension in univariate analysis cannot be attributed only to these exposures because, aside from possible confounders, patients may have had other comorbidities. To overcome this limitation, we extracted data from reported multivariate analyses. However, because their scarcity, we could not synthesize adjusted estimates. Second, most published studies are sourced from China and may be less generalizable to populations in other parts of the world. Moreover, 3 of the included studies provided data on demographic or biochemical parameters such as blood pressure values, glycemic control markers, duration of disease, or smoking; however, we could not perform an adjusted analysis because these studies did not coincide with the assessed outcomes. Finally, auxiliary reasons for the observed risks could be a higher prevalence of obesity, cardiovascular, and renal disease in these patients. Additionally, elderly individuals are overrepresented among Covid-19 patients requiring hospital admission and critical care, where diabetes and hypertension is highest. Thus, the risks attributed to these comorbidities in relation to Covid-19 might be confounded, as our DAG suggests \[[@CIT0027]\].

Comparison with previous studies {#s21}
--------------------------------

### Diabetes.  {#s22}

Two smaller reviews noted a prevalence of diabetes between 10% and 11.9% in Covid-19, comparable to our estimates \[[@CIT0016], [@CIT0017]\]. However, our estimates are lower than those reported by Shi et al. of 14.3% \[[@CIT0043]\]. Furthermore, compared with the 9.3% global community prevalence of diabetes \[[@CIT0047]\], our study found a 12% prevalence, suggesting a higher figure. In contrast to author-defined severe Covid-19, dichotomous outcomes of disease severity such as ICU admission and mortality were significantly elevated (\~2- and \~3-fold, respectively) in diabetes. This is of particular interest because Huang et al. noted an increased risk of a composite poor outcome in patients with diabetes, which included severe Covid-19 as one of the outcomes. However, our analysis suggests that severe Covid-19 is a largely heterogenous outcome that lacks interpretability and may not accurately reflect the outcomes of interest \[[@CIT0020]\].

Additionally, 1 study of 1382 Covid-19 patients with diabetes found a 2.79-fold risk of admission to the ICU \[[@CIT0048]\], higher than our findings of 1.96-fold in 8890 patients. However, the reported risk of Covid-19 mortality in diabetes was 2.85- to 3.21-fold, consistent with our findings \[[@CIT0009], [@CIT0048]\]. Other meta-analyses did not report ICU admission or mortality risk estimates \[[@CIT0016], [@CIT0049]\]. Comparatively, the SARS epidemic in 2003, also caused by a betacoronavirus, was associated with a 3-fold risk of poor outcomes in the presence of diabetes, the highest among all comorbidities \[[@CIT0050]\].

The heightened Covid-19 risks in diabetes are multifactorial. Diabetes may facilitate the entry of SARS-CoV-2 by increased expression of ACE2 surface receptors because of the disease itself and the treatment strategies used \[[@CIT0010], [@CIT0011], [@CIT0051]\]. Furthermore, diabetes leads to dysregulation of immune responses by cytokines such as IL-6 and attenuating anti-inflammatory signaling leading to increased end-organ injury \[[@CIT0010], [@CIT0011], [@CIT0054]\]. Given that obesity and diabetes often coexist \[[@CIT0057]\], at least part of the heightened Covid-19 risks in diabetes could be attributed to comorbid obesity, an emerging independent risk factor for severe Covid-19 \[[@CIT0058]\]. Furthermore, because diabetes is independently associated with comorbidities, Covid-19 acts as an additional insult to preexisting comorbidities. For instance, hypoglycemia, a comorbidity of diabetes, may be masked by hypoglycemia unawareness in asymptomatic Covid-19 carriers with diabetes mellitus with serious clinical consequences \[[@CIT0006]\].

### Hypertension.  {#s23}

Initial reports indicated a 26% to 30% prevalence of hypertension in Covid-19 patients \[[@CIT0009], [@CIT0059]\]. Published data from systematic reviews reported a 17.1% to 20% prevalence of hypertension in Covid-19, comparable to our estimates of 17% in our analysis of 12 709 patients \[[@CIT0016], [@CIT0017]\]. In the inpatient setting, our results suggest that hypertension prevalence could be up to 26%, which is still lower compared with recent data from the United States of \~50% \[[@CIT0060], [@CIT0061]\]. Moreover, our estimates were lower than the 31.1% global prevalence of hypertension, which could suggest an average (or below average) risk of Covid-19 \[[@CIT0062]\].

We found a nonconclusive risk of severe Covid-19 in hypertension. Other reports suggest a higher risk of severe Covid-19 in hypertensives, of approximately 2.3-fold \[[@CIT0017], [@CIT0049]\]. However, after analyzing the important variation in the parameters used to define severity, we conclude that these estimates are noninterpretable. In contrast, the risk of ICU admission, which we consider a more reliable proxy of Covid-19 severity, was elevated in our analysis. Finally, we found an elevated risk of Covid-19 mortality associated with hypertension that was not described in other meta-analyses but is comparable to the 2.4- to 3.0-fold risk reported in primary studies \[[@CIT0009], [@CIT0063]\].

The observed risk of Covid-19 in patients with hypertension is likely multifactorial. The underlying immune dysregulation, with a higher propensity for an exaggerated immune response to viral exposure, resulting in a cytokine storm and end-organ injury could be a major contributor to this risk \[[@CIT0064], [@CIT0065]\]. Additional contributors may include a higher sympathetic drive, hyperactivity of T-helper cells, increased ACE2 expression, and an enhanced angiotensin II/angiotensin 1-7 ratio reducing anti-inflammatory effects of the latter, and increased pro-inflammatory action of angiotensin II \[[@CIT0066]\].

Implications for future research and clinical practice {#s24}
------------------------------------------------------

Future studies of Covid-19 patients with diabetes or hypertension should report on patient characteristics, subtype of hypertension or diabetes, duration of disease, medications used, and disease control markers. This information would not only be valuable for future systematic reviews but also assist frontline clinicians in individualizing the Covid-19 risks faced by their patients. Furthermore, future studies reporting multivariate analyses should consider our proposed minimal sufficient adjustment sets to avoid unnecessary or overadjustment of prognosticators. To date, the risk for severe Covid-19 faced by patients with diabetes and hypertension is unclear because of the large heterogeneity in the author definitions of Covid-19 severity. Until a universal definition of Covid-19 severity is adopted, we propose using the ICU admission rate as a more objective way to define severity.

Conclusion {#s25}
==========

Compared with previous reviews, our results suggest a lower prevalence of diabetes and hypertension in hospitalized Covid-19 patients. These patients face a higher risk of poor outcomes compared with those without these comorbidities. However, the body of evidence are at high risk of bias and provide low confidence in the estimates.
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ACE2

:   angiotensin-converting enzyme 2

CI

:   confidence interval

Covid-19

:   coronavirus disease 2019

DAG

:   directed acyclic graph

ICU

:   intensive care unit

RR

:   relative risk

SARS-CoV-2

:   severe acute respiratory syndrome coronavirus
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